# Clinical Study of UTD1 Injection in Combination With Capecitabine in Patients With Advanced and Metastatic Breast Cancer

> **NCT02253459** · PHASE3 · COMPLETED · sponsor: **Beijing Biostar Pharmaceuticals Co., Ltd.** · enrollment: 405 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** UTD1 Injection plus capecitabine
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT02253459
- **Lead sponsor:** Beijing Biostar Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2016-09
- **Final completion:** 2018-12-15
- **Target enrollment:** 405 (ACTUAL)
- **Last updated:** 2019-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02253459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02253459, "Clinical Study of UTD1 Injection in Combination With Capecitabine in Patients With Advanced and Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02253459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*